A Phase 1 interventional study of Semaglutide B, 1.34 mg/mL and Semaglutide D, 1.0 mg/mL in Healthy Volunteers (Diabetes Mellitus, Type 2), sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.
Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 80th largest by enrollment, is one of 4 that started in 2022, is one of 36 in phase 1, and was the 66th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 20 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 7 · Phase 3 27 · Phase 4 10
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 100 across the 82 interventional studies. Of the 66 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 82 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
642 studies in Diabetes Mellitus by Novo Nordisk A/S: 2 open now, 3 under way, 1 of them phase 3. Of 636 finished, 163 (26%) have results posted.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 472nd largest by enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2022, is one of 206 in phase 1, and was the 639th registered.
Novo Nordisk A/S’s Diabetes Mellitus studies by the year they started, since 1989.
6 of the studies testing semaglutide in Diabetes Mellitus that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06387199Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | 2027-01 |
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT07401992Hospital Universitario Dr. Jose E. GonzalezEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies testing semaglutide in Diabetes Mellitus, from their registry updates:
Among Novo Nordisk A/S’s 642 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg). The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each period. Participants will have to fast for at least 6 hours overnight with only water allowed before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1 and Period 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abuse or intake of alcohol, defined as any of the below:
Abuse or intake of drugs, defined as any of the below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Semaglutide B, 1.34 mg/mL · Drug: Semaglutide D, 1.0 mg/mL
Drug: Semaglutide D, 1.0 mg/mL · Drug: Semaglutide B, 1.34 mg/mL
Drug page: Semaglutide
Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Drug page: Semaglutide
Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg
Measured in h\*nmol/L
Time frame: 0-840 hours after a single dose of s.c. semaglutide 0.5 mg
Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration
Measured in nmol/L
Time frame: 0-840 hours after a single dose of s.c. semaglutide 0.5 mg
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Aug 2022, 7 months.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 7 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide